v3.26.1
ACQUISITIONS AND DIVESTITURES (Tables)
 6 Months Ended
Jun. 27, 2026
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]  
Schedule of Purchase Price Allocation
The preliminary purchase price allocations were as follows:
PathoQuest SAS(1)
Cambodian NHP Supplier(1)
April 17, 2026January 14, 2026
(in thousands)
Trade receivables$866 $— 
Inventories841 114,688 
Other current assets (excluding cash)2,034 — 
Property, plant and equipment, net2,223 9,858 
Operating lease right-of-use asset, net1,941 — 
Goodwill (2)
41,574 335,906 
Intangible assets, net20,033 — 
Other assets (3)
8,598 282,517 
Deferred revenue(881)— 
Other current liabilities (6,259)(2,414)
Operating lease right-of-use liabilities(1,954)— 
Other long-term liabilities (4)
(1,455)(233,296)
Total purchase price allocation$67,561 $507,259 
(1) Purchase price allocation is preliminary and subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed, including certain obligations. Any additional adjustments to the purchase price allocation will be made as soon as practicable but no later than one year from the date of acquisition.
(2) The goodwill resulting from these transactions is primarily attributable to the potential growth of the Company’s segments from new customers introduced to the acquired businesses or synergies to be realized from acquiring an internal supplier servicing the DSA business and the assembled workforce of the acquirees. With the exception of $102.6 million of goodwill related to the Cambodian NHP Supplier, which will be deductible for tax purposes upon making the remaining deferred payments, goodwill is not deductible for tax purposes.
(3) Other assets acquired resulting from Cambodian NHP Supplier include $283.0 million of biological assets, which will be amortized over an estimated eleven year useful life.
(4) Cambodian NHP Supplier other long-term liabilities include pre-acquisition uncertain tax positions of the seller associated with the acquired assets.
Schedule of Business Combination, Intangible Asset, Acquired, Finite-Lived
The definite-lived intangible assets acquired were as follows:
PathoQuest SAS
Definite-Lived Intangible Assets(in thousands)
Client relationships$5,085 
Developed technology14,948 
Total definite-lived intangible assets$20,033 
Weighted Average Amortization Life
Client relationships13
Developed technology13
Total definite-lived intangible assets13
Schedule of Disposal Groups, Including Discontinued Operations
As a result of the divestitures, the Company derecognized the net assets of the European Discovery Divestiture and CDMO and Cell Solutions Divestiture as follows:
European Discovery Divestiture
CDMO and Cell Solutions Divestiture
May 22, 2026May 6, 2026
(in thousands)
Assets
Current assets$50,464 $67,330 
Property, plant, and equipment, net 49,522 294 
Operating lease right-of-use assets, net19,083 — 
Goodwill 37,701 — 
Intangible assets, net53,502 — 
Other assets 1,268 14,285 
Total assets$211,540 $81,909 
Liabilities
Current liabilities 37,177 33,709 
Operating lease right-of-use liabilities17,769 23,316 
Long-term liabilities 31,671 2,925 
Total liabilities$86,617 $59,950